Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)
Key facts
- Who runs it
- Ohio State University
- Where
- Columbus, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 56 people enrolled
- Started
- 19 Oct 2023
- Ended
- 1 May 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Patient-led Insulin (intervention group)
- Provider-led Insulin (standard care)
- Record updated
- 2 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Pregnant individuals with a diagnosis of Gestational diabetes mellitus (GDM) between 20 0/7 to 31 6/7 - 32 6/7 weeks and requiring initiation of basal insulin initiation as determined by provider
- Patients not on insulin or insulin initiation within 7 days of consent and randomization
- ≥ 18 years old with the ability to give informed consent
- Diagnosed with GDM during pregnancy by a one-hour 50-gram glucose challenge test ≥200 mg/dL at greater than 20 weeks of gestation or two elevated values on a 3-hour or a 100-gram glucose tolerance test at greater than 20 weeks of gestation
- English or Spanish speaking
- Receiving prenatal care at OSU or an affiliated clinic where Electronic Health Records (EHR) can be accessed
Who cannot take part
- Type 1 or 2 diabetes
- Insulin allergy
- Not English or Spanish speaking
Where in United States
- The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal MedicineColumbus, United States
About the trial
What the trial wants to find out
We propose a pragmatic, unblinded, randomized controlled, single center trial of 56 pregnant individuals with Gestational diabetes mellitus (GDM). Our study proposes a pragmatic randomized control trial of patient led rapid titration of basal insulin compared to standard therapy. There is a planned subgroup analysis of patients with and without concomitant metformin usage. Patients will continue routine clinic visits. Patients who are initiated on basal insulin or started on night-time basal insulin within 7 days will be approached about the study. Patients who agree to be enrolled will sign informed consent.
The 2 groups in the trial
- Patient-led self-titration of insulinTreatment being tested
Individuals randomized to this arm will initiate night-time insulin of 10 units. The type of basal insulin will be left to the discretion of the provider with levemir or glargine preferred over NPH. On day 0 of initiation of insulin, the patient will initiate night-time (or prior to sleep if alternate sleep schedule) insulin of 10 units (glargine, detemir, or NPH). Patient will check their fasting blood glucose in the morning and record their values. If the value is below 70 they will decrease their insulin dosage that night by 2 units; if the value is above 95 they will increase their insulin dosage that night by 2 units; and if the value is between 70 and 95, they will maintain the same insulin dosage that night. The patients will continue this algorithm for the remainder of the pregnancy. If the patient does not have a fasting blood glucose, the patient will maintain the dose of basal insulin at the prior dose.
Treatment: Patient-led Insulin (intervention group)
- Standard of careExisting treatment, for comparison
Individuals randomized to this arm will receive standard care and titration of insulin will be determined by the individual providers.
Treatment: Provider-led Insulin (standard care)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes
- Publications
- Patient-Led Insulin Titration for Glycemic Management With Gestational Diabetes Mellitus: A Randomized Controlled Trial.Obstetrics and gynecology, 2026
- Record updated
- 2 July 2025